Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Income towards Common Stockholders: 2021-2024

Historic Net Income towards Common Stockholders for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Net Income towards Common Stockholders fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • ARS Pharmaceuticals' Net Income towards Common Stockholders amounted to $8.0 million in FY2024, which was up 114.71% from -$54.4 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Net Income towards Common Stockholders peaked at $8.0 million during FY2024, and registered a low of -$54.4 million during FY2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$27.3 million, with a median of -$35.5 million in 2022.
  • In the last 5 years, ARS Pharmaceuticals' Net Income towards Common Stockholders plummeted by 82.56% in 2022 and then spiked by 114.71% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$19.5 million in 2021, then tumbled by 82.56% to -$35.5 million in 2022, then slumped by 53.07% to -$54.4 million in 2023, then soared by 114.71% to $8.0 million in 2024.